Lp(a) in ASCVD and Guideline Recommendations

FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.

Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.

Nearly 3 in 4 bariatric surgery candidates had clinical obesity, a phenotype that BMI alone did not distinguish from preclinical obesity.

Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.

A review of 47 endometriosis guidelines found most came from high-income settings and diverged on biomarkers, repeat surgery, and fertility referral.

The meeting covered several topics in eye care, including how artificial intelligence (AI) can play a part in eye care.

A meta-analysis of 27 trials found a 15% cardiovascular risk reduction per 10-mm Hg lower systolic BP, with no added risk of kidney failure.

In a Japanese registry of 1235 patients with AMI treated with PCI, Lp(a) of 24 mg/dL or higher independently predicted MACE and HF hospitalization.